Ceritinib Response Seen in Study of Brain Metastases in ALK-Positive NSCLC

“The efficacy of ceritinib was evaluated in patients who have ALK-positive non-small cell lung cancer with active brain metastases.”
— Read on www.pharmacytimes.com/conferences/esmo-congress-2019/https//www.pharmacytimes.com/

Leave a Reply

Your email address will not be published. Required fields are marked *